🇺🇸 FDA

Intelligence · Patent portfolio

Acadia Pharmaceuticals Patents

Full USPTO pharma patent portfolio for Acadia Pharmaceuticals — grant dates, expiration, and drug cross-links.

Patents
77
Expiring ≤24m
9

Quick answer

Acadia Pharmaceuticals has 77 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 9 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 2

  1. US 11844764

    Agitation process for preparing a carbetocin drug product

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11827600

    Crystalline forms of trofinetide

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11452721

    Formulations of pimavanserin

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11161826

    Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11135211

    Pimavanserin for treating impulse control disorder

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11091473

    Compounds for pain treatment, compositions comprising same, and methods of using same

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10953000

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10849891

    Formulations of pimavanserin

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10646480

    Formulations of pimavanserin

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10525046

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10517860

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10449185

    Formulations of pimavanserin

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10028944

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9765053

    Methods of treatment using selective 5-HT2A inverse agonists

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9757366

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9670209

    Muscarinic agonists

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9566271

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9522906

    Tetrahydroquinoline analogues as muscarinic agonists

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9446037

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9296694

    Azacyclic compounds

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9211289

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9061981

    Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9050343

    Combination of pimavanserin and risperidone for the treatment of psychosis

    Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8921393

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8822548

    Compounds with activity at estrogen receptors

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8680115

    Tetrahydroquinoline analogues as muscarinic agonists

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8618130

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8470872

    Compounds with activity at estrogen receptors

    Expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8377959

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8236960

    Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms

    Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8227487

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8101651

    Compounds with activity at estrogen receptors

    Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8008323

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Aug 25 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7994193

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7923564

    Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms

    Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7875632

    Selective serotonin receptor inverse agonists as therapeutics for disease

    Expires Mon Jan 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7868176

    Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation

    Expires Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7863296

    Selective serotonin receptor inverse agonists as therapeutics for disease

    Expires Mon Dec 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7825265

    Compounds with activity at estrogen receptors

    Expires Mon Oct 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7820695

    Selective serotonin receptor inverse agonists as therapeutics for disease

    Expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7790899

    Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms

    Expires Mon Sep 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7732462

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7732615

    N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms

    Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7727999

    Spiroazacyclic compounds as monoamine receptor modulators

    Expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7713995

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7659285

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Acadia Pharmaceuticals have?

77 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Acadia Pharmaceuticals patents expire?

9 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.